B-cell receptor specific for Adeno-associated virus 2 capsid and SIINFEKL epitopes (Anti-AAV2/SIINFEKL BCR)

B-cell receptors (BCRs) specific for Adeno-associated virus serotype 2 (AAV2) capsid epitopes and model antigens like SIINFEKL are critical mediators of the humoral immune response in gene therapy contexts. These receptors are membrane-bound immunoglobulins that recognize viral capsid proteins, triggering B-cell activation and the subsequent production of neutralizing antibodies (NAbs) that can severely limit the efficacy of AAV-mediated gene delivery (Mingozzi & High, 2013, Nature Reviews Genetics). The SIINFEKL peptide, derived from ovalbumin, is frequently used as a model epitope in these systems to track antigen-specific immune responses with high sensitivity, allowing researchers to study the mechanisms of B-cell memory and tolerance (Herzog et al., 2019, Frontiers in Immunology). In clinical practice, these BCRs are targets for modulation to prevent or overcome pre-existing immunity, which affects a significant portion of the human population (Leborgne et al., 2020, Nature Medicine). Therapeutic strategies include the use of B-cell depleting agents like rituximab or the development of tolerogenic nanoparticles designed to specifically silence B cells expressing these receptors. Successfully managing these BCR-mediated responses is essential for the safety and durability of genetic medicines.

Other names

AAV-specific B-cell receptorAnti-AAV2 BCRSIINFEKL-specific BCRAntigen-specific B-cell receptor

Targeting of B-cell surface markers to induce depletion, inhibition of intracellular signaling pathways like BTK, or enzymatic cleavage of the resulting antibodies to mitigate the humoral response.